HealthcareServices

Global Diagnostic Biomarkers Market Set for Strong Expansion, Reaching $155.92 Billion With 15.5% CAGR by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the diagnostic biomarkers market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Diagnostic Biomarkers Market’s size between 2026 and 2030?

The diagnostic biomarkers market has experienced substantial growth in recent years. Its value is expected to rise from $75.46 billion in 2025 to $87.47 billion in 2026, with a compound annual growth rate (CAGR) of 15.9%. This historical growth can be linked to several factors, including the expansion of molecular diagnostics, increased cancer research, the limitations of traditional diagnostics, a growing burden of chronic diseases, and studies on biomarker validation.

The diagnostic biomarkers market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $155.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.5%. Key factors driving this expansion during the forecast period include progress in omics technologies, the rise of personalized medicine, AI-driven biomarker discovery, regulatory clearances for new biomarkers, and the need for predictive diagnostics. Prominent trends expected over this period encompass the growing embrace of precision diagnostic biomarkers, wider application of genomic and proteomic biomarkers, increased use of biomarkers in cancer diagnostics, the merging of biomarker data with clinical analytics, and an escalating call for early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp

Which Drivers Are Shaping Strategic Decisions In The Diagnostic Biomarkers Market?

The expanding occurrence of cancer is propelling the future growth of the diagnostic biomarkers market. This rise in cancer cases stems from factors like an aging demographic, shifts in lifestyle, environmental exposures, and enhanced diagnostic capabilities. Within cancer management, diagnostic biomarkers are vital for facilitating early detection, accurate diagnosis, and individualized treatment plans, thereby improving patient outcomes. For example, data from January 2024, provided by the American Cancer Society, a US-based nonprofit cancer advocacy organization, indicated a rise in cancer cases to 2,001,140, up from 1,958,310 in 2023, marking a 2.19% increase. This increasing prevalence of cancer is thus a key driver for the diagnostic biomarkers market.

What Segment Classifications Make Up The Diagnostic Biomarkers Market?

The diagnostic biomarkers market covered in this report is segmented –

1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Application: Oncology, Metabolic Disease, Neurological Disease

3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers

2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers

3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers

Which Trends Are Influencing The Development Of The Diagnostic Biomarkers Market?

Leading companies within the diagnostic biomarkers market are concentrating on developing non-invasive testing methodologies, including blood-based biomarker tests, to enhance patient comfort and accessibility alongside personalized treatment strategies. A blood-based biomarker test is a diagnostic instrument that examines specific biological markers found in the blood to detect or monitor conditions, such as Alzheimer’s, with minimal invasiveness. For instance, in July 2023, Quanterix Corporation, a US-based life sciences company, introduced LucentAD, a blood-based biomarker test intended to support healthcare providers in diagnosing Alzheimer’s disease (AD) in patients who show early cognitive symptoms. This test quantifies plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker connected to amyloid pathology in the brain, which is a significant indicator of AD. By offering a diagnostic tool that is less invasive and more accessible compared to conventional approaches like cerebrospinal fluid analysis or amyloid positron emission tomography, LucentAD endeavors to streamline the evaluation process for individuals suspected of having Alzheimer’s.

Which Leading Companies Dominate The Diagnostic Biomarkers Market Share?

Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report

How Does The Diagnostic Biomarkers Market Perform Across Major Global Regions?

North America was the largest region in the diagnostic biomarkers market in 2025. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Diagnostic Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21171&type=smp

Browse Through More Reports Similar to the Global Diagnostic Biomarkers Market 2026, By The Business Research Company

Oncology Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Cancer Biomarker Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795